Skip to main content
Top
Published in: Gut Pathogens 1/2016

Open Access 01-12-2016 | Research

Effect of antibiotic pre-treatment and pathogen challenge on the intestinal microbiota in mice

Authors: Tadasu Iizumi, Takako Taniguchi, Wataru Yamazaki, Geraldine Vilmen, Alexander V. Alekseyenko, Zhan Gao, Guillermo I. Perez Perez, Martin J. Blaser

Published in: Gut Pathogens | Issue 1/2016

Login to get access

Abstract

Background

More than 50 years after the discovery of antibiotics, bacterial infections have decreased substantially; however, antibiotics also may have negative effects such as increasing susceptibility to pathogens. An intact microbiome is an important line of defense against pathogens. We sought to determine the effect of orally administered antibiotics both on susceptibility to pathogens and on impact to the microbiome. We studied Campylobacter jejuni, one of the most common causes of human diarrhea, and Acinetobacter baumannii, which causes wound infections. We examined the effects of antibiotic treatment on the susceptibility of mice to those pathogens as well as their influence on the mouse gut microbiome.

Results

In C57/BL6 mice models, we explored the effects of pathogen challenge, and antibiotic treatment on the intestinal microbiota. Mice were treated with either ciprofloxacin, penicillin, or water (control) for a 5-day period followed by a 5-day washout period prior to oral challenge with C. jejuni or A. baumannii to assess antibiotic effects on colonization susceptibility. Mice were successfully colonized with C. jejuni more than 118 days, but only transiently with A. baumannii. These challenges did not lead to any major effects on the composition of the gut microbiota. Although antibiotic pre-treatment did not modify pathogen colonization, it affected richness and community structure of the gut microbiome. However, the antibiotic dysbiosis was significantly reduced by pathogen challenge.

Conclusions

We conclude that despite gut microbiota disturbance, susceptibility to gut colonization by these pathogens was unchanged. The major gut microbiome disturbance produced by antibiotic treatment may be reduced by colonization with specific microbial taxa.
Appendix
Available only for authorised users
Literature
1.
go back to reference Luckey TD. Introduction to intestinal microecology. Am J Clin Nutr. 1972;25(12):1292–4.PubMed Luckey TD. Introduction to intestinal microecology. Am J Clin Nutr. 1972;25(12):1292–4.PubMed
2.
go back to reference Ley RE, Lozupone CA, Hamady M, Knight R, Gordon JI. Worlds within worlds: evolution of the vertebrate gut microbiota. Nat Rev Microbiol. 2008;6(10):776–88.CrossRefPubMedPubMedCentral Ley RE, Lozupone CA, Hamady M, Knight R, Gordon JI. Worlds within worlds: evolution of the vertebrate gut microbiota. Nat Rev Microbiol. 2008;6(10):776–88.CrossRefPubMedPubMedCentral
3.
6.
go back to reference Hooper LV, Macpherson AJ. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol. 2010;10(3):159–69.CrossRefPubMed Hooper LV, Macpherson AJ. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol. 2010;10(3):159–69.CrossRefPubMed
7.
go back to reference Hicks LA, Taylor TH Jr, Hunkler RJ. U.S. outpatient antibiotic prescribing, 2010. N Engl J Med. 2013;368(15):1461–2.CrossRefPubMed Hicks LA, Taylor TH Jr, Hunkler RJ. U.S. outpatient antibiotic prescribing, 2010. N Engl J Med. 2013;368(15):1461–2.CrossRefPubMed
8.
go back to reference Bohnhoff M, Miller CP. Enhanced susceptibility to Salmonella infection in streptomycin-treated mice. J Infect Dis. 1962;111:117–27.CrossRefPubMed Bohnhoff M, Miller CP. Enhanced susceptibility to Salmonella infection in streptomycin-treated mice. J Infect Dis. 1962;111:117–27.CrossRefPubMed
9.
go back to reference Robinson CJ, Young VB. Antibiotic administration alters the community structure of the gastrointestinal micobiota. Gut Microbes. 2010;1(4):279–84.CrossRefPubMed Robinson CJ, Young VB. Antibiotic administration alters the community structure of the gastrointestinal micobiota. Gut Microbes. 2010;1(4):279–84.CrossRefPubMed
10.
go back to reference Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 2015;517(7533):205–8.CrossRefPubMed Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 2015;517(7533):205–8.CrossRefPubMed
11.
go back to reference Cho I, Yamanishi S, Cox L, Methe BA, Zavadil J, Li K, Gao Z, Mahana D, Raju K, Teitler I, et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature. 2012;488(7413):621–6.CrossRefPubMedPubMedCentral Cho I, Yamanishi S, Cox L, Methe BA, Zavadil J, Li K, Gao Z, Mahana D, Raju K, Teitler I, et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature. 2012;488(7413):621–6.CrossRefPubMedPubMedCentral
12.
go back to reference Cox LM, Yamanishi S, Sohn J, Alekseyenko AV, Leung JM, Cho I, Kim SG, Li H, Gao Z, Mahana D, et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell. 2014;158(4):705–21.CrossRefPubMedPubMedCentral Cox LM, Yamanishi S, Sohn J, Alekseyenko AV, Leung JM, Cho I, Kim SG, Li H, Gao Z, Mahana D, et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell. 2014;158(4):705–21.CrossRefPubMedPubMedCentral
13.
go back to reference Wagenaar JA, French NP, Havelaar AH. Preventing Campylobacter at the source: why is it so difficult? Clin Infect Dis. 2013;57(11):1600–6.CrossRefPubMed Wagenaar JA, French NP, Havelaar AH. Preventing Campylobacter at the source: why is it so difficult? Clin Infect Dis. 2013;57(11):1600–6.CrossRefPubMed
14.
go back to reference Dasti JI, Tareen AM, Lugert R, Zautner AE, Gross U. Campylobacter jejuni: a brief overview on pathogenicity-associated factors and disease-mediating mechanisms. Int J Med Microbiol. 2010;300(4):205–11.CrossRefPubMed Dasti JI, Tareen AM, Lugert R, Zautner AE, Gross U. Campylobacter jejuni: a brief overview on pathogenicity-associated factors and disease-mediating mechanisms. Int J Med Microbiol. 2010;300(4):205–11.CrossRefPubMed
15.
go back to reference Allos BM. Campylobacter jejuni infections: update on emerging issues and trends. Clin Infect Dis. 2001;32(8):1201–6.CrossRefPubMed Allos BM. Campylobacter jejuni infections: update on emerging issues and trends. Clin Infect Dis. 2001;32(8):1201–6.CrossRefPubMed
16.
go back to reference Gulen TA, Guner R, Celikbilek N, Keske S, Tasyaran M. Clinical importance and cost of bacteremia caused by nosocomial multi drug resistant Acinetobacter baumannii. Int J Infect Dis. 2015;38:32–5.CrossRefPubMed Gulen TA, Guner R, Celikbilek N, Keske S, Tasyaran M. Clinical importance and cost of bacteremia caused by nosocomial multi drug resistant Acinetobacter baumannii. Int J Infect Dis. 2015;38:32–5.CrossRefPubMed
17.
go back to reference Martin-Loeches I, Diaz E, Valles J. Risks for multidrug-resistant pathogens in the ICU. Curr Opin Crit Care. 2014;20(5):516–24.CrossRefPubMed Martin-Loeches I, Diaz E, Valles J. Risks for multidrug-resistant pathogens in the ICU. Curr Opin Crit Care. 2014;20(5):516–24.CrossRefPubMed
18.
go back to reference Ayats J, Corbella X, Ardanuy C, Dominguez MA, Ricart A, Ariza J, Martin R, Linares J. Epidemiological significance of cutaneous, pharyngeal, and digestive tract colonization by multiresistant Acinetobacter baumannii in ICU patients. J Hosp Infect. 1997;37(4):287–95.CrossRefPubMed Ayats J, Corbella X, Ardanuy C, Dominguez MA, Ricart A, Ariza J, Martin R, Linares J. Epidemiological significance of cutaneous, pharyngeal, and digestive tract colonization by multiresistant Acinetobacter baumannii in ICU patients. J Hosp Infect. 1997;37(4):287–95.CrossRefPubMed
19.
go back to reference Korlath JA, Osterholm MT, Judy LA, Forfang JC, Robinson RA. A point-source outbreak of campylobacteriosis associated with consumption of raw milk. J Infect Dis. 1985;152(3):592–6.CrossRefPubMed Korlath JA, Osterholm MT, Judy LA, Forfang JC, Robinson RA. A point-source outbreak of campylobacteriosis associated with consumption of raw milk. J Infect Dis. 1985;152(3):592–6.CrossRefPubMed
20.
go back to reference Black RE, Levine MM, Clements ML, Hughes TP, Blaser MJ. Experimental Campylobacter jejuni infection in humans. J Infect Dis. 1988;157(3):472–9.CrossRefPubMed Black RE, Levine MM, Clements ML, Hughes TP, Blaser MJ. Experimental Campylobacter jejuni infection in humans. J Infect Dis. 1988;157(3):472–9.CrossRefPubMed
21.
go back to reference Gao Z, Perez-Perez GI, Chen Y, Blaser MJ. Quantitation of major human cutaneous bacterial and fungal populations. J Clin Microbiol. 2010;48(10):3575–81.CrossRefPubMedPubMedCentral Gao Z, Perez-Perez GI, Chen Y, Blaser MJ. Quantitation of major human cutaneous bacterial and fungal populations. J Clin Microbiol. 2010;48(10):3575–81.CrossRefPubMedPubMedCentral
22.
go back to reference He Y, Chen CY. Quantitative analysis of viable, stressed and dead cells of Campylobacter jejuni strain 81-176. Food Microbiol. 2010;27(4):439–46.CrossRefPubMed He Y, Chen CY. Quantitative analysis of viable, stressed and dead cells of Campylobacter jejuni strain 81-176. Food Microbiol. 2010;27(4):439–46.CrossRefPubMed
23.
go back to reference Chuang YC, Chang SC, Wang WK. High and increasing Oxa-51 DNA load predict mortality in Acinetobacter baumannii bacteremia: implication for pathogenesis and evaluation of therapy. PLoS ONE. 2010;5(11):e14133.CrossRefPubMedPubMedCentral Chuang YC, Chang SC, Wang WK. High and increasing Oxa-51 DNA load predict mortality in Acinetobacter baumannii bacteremia: implication for pathogenesis and evaluation of therapy. PLoS ONE. 2010;5(11):e14133.CrossRefPubMedPubMedCentral
24.
go back to reference Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Pena AG, Goodrich JK, Gordon JI, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7(5):335–6.CrossRefPubMedPubMedCentral Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Pena AG, Goodrich JK, Gordon JI, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7(5):335–6.CrossRefPubMedPubMedCentral
25.
go back to reference Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 2010;26(19):2460–1.CrossRefPubMed Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 2010;26(19):2460–1.CrossRefPubMed
26.
go back to reference Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Lozupone CA, Turnbaugh PJ, Fierer N, Knight R. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proc Natl Acad Sci USA. 2011;108(Suppl 1):4516–22.CrossRefPubMed Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Lozupone CA, Turnbaugh PJ, Fierer N, Knight R. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proc Natl Acad Sci USA. 2011;108(Suppl 1):4516–22.CrossRefPubMed
27.
go back to reference Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12(6):R60.CrossRefPubMedPubMedCentral Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12(6):R60.CrossRefPubMedPubMedCentral
28.
go back to reference Seifert H, Baginski R, Schulze A, Pulverer G. The distribution of Acinetobacter species in clinical culture materials. Zentralbl Bakteriol. 1993;279(4):544–52.CrossRefPubMed Seifert H, Baginski R, Schulze A, Pulverer G. The distribution of Acinetobacter species in clinical culture materials. Zentralbl Bakteriol. 1993;279(4):544–52.CrossRefPubMed
29.
30.
go back to reference Blaser MJ, Duncan DJ, Warren GH, Wang WL. Experimental Campylobacter jejuni infection of adult mice. Infect Immun. 1983;39(2):908–16.PubMedPubMedCentral Blaser MJ, Duncan DJ, Warren GH, Wang WL. Experimental Campylobacter jejuni infection of adult mice. Infect Immun. 1983;39(2):908–16.PubMedPubMedCentral
31.
go back to reference Stanfield JT, McCardell BA, Madden JM. Campylobacter diarrhea in an adult mouse model. Microb Pathog. 1987;3(3):155–65.CrossRefPubMed Stanfield JT, McCardell BA, Madden JM. Campylobacter diarrhea in an adult mouse model. Microb Pathog. 1987;3(3):155–65.CrossRefPubMed
32.
go back to reference Lohans CT, van Belkum MJ, Li J, Vederas JC. Characterization of bacterial antimicrobial peptides active against Campylobacter jejuni. Can J Chem. 2015;93(4):381–8.CrossRef Lohans CT, van Belkum MJ, Li J, Vederas JC. Characterization of bacterial antimicrobial peptides active against Campylobacter jejuni. Can J Chem. 2015;93(4):381–8.CrossRef
33.
go back to reference Behra-Miellet J, Dubreuil L, Jumas-Bilak E. Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams. Int J Antimicrob Agents. 2002;20(5):366–74.CrossRefPubMed Behra-Miellet J, Dubreuil L, Jumas-Bilak E. Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams. Int J Antimicrob Agents. 2002;20(5):366–74.CrossRefPubMed
34.
35.
go back to reference Bryskier A. Anti-anaerobic activity of antibacterial agents. Expert Opin Investig Drugs. 2001;10(2):239–67.CrossRefPubMed Bryskier A. Anti-anaerobic activity of antibacterial agents. Expert Opin Investig Drugs. 2001;10(2):239–67.CrossRefPubMed
Metadata
Title
Effect of antibiotic pre-treatment and pathogen challenge on the intestinal microbiota in mice
Authors
Tadasu Iizumi
Takako Taniguchi
Wataru Yamazaki
Geraldine Vilmen
Alexander V. Alekseyenko
Zhan Gao
Guillermo I. Perez Perez
Martin J. Blaser
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Gut Pathogens / Issue 1/2016
Electronic ISSN: 1757-4749
DOI
https://doi.org/10.1186/s13099-016-0143-z

Other articles of this Issue 1/2016

Gut Pathogens 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine